Joerg Reinhardt - Novartis Independent Non-Executive Chairman of the Board
NVSN Stock | MXN 1,540 0.00 0.00% |
Chairman
Mr. Joerg Reinhardt, Ph.D., was Independent NonExecutive Chairman of the Board of Novartis Inc. since August 1, 2013. He is also Chairman of the Research Development Committee and Chairman of the Board of Trustees of the Novartis Foundation. Mr. Reinhardt is Chairman of the board of trustees of the Institute of Molecular and Clinical Ophthalmology Basel, Switzerland. From 2010 to mid2013, he was Chairman of the Board of Management and the Executive Committee of Bayer HealthCare, Germany. Prior to that, he was Chief Operating Officer of Novartis from 2008 to 2010, and Head of the Vaccines and Diagnostics Division of Novartis from 2006 to 2008. Mr. Reinhardt is a nonexecutive board member of Swiss Re, Switzerland, and a member of the European Advisory Panel of Temasek, Singapore. Additionally, he was a member of the board of directors of Lonza Group AG in Switzerland from 2012 to 2013, Chairman of the Board of the Genomics Institute of the Novartis Research Foundation in the United States from 2000 to 2010, and a member of the supervisory board of MorphoSys AG in Germany from 2001 to 2004 since 2013.
Age | 63 |
Tenure | 11 years |
Professional Marks | Ph.D |
Phone | 41 61 324 1111 |
Web | https://www.novartis.com |
Novartis Management Efficiency
The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 11 records | CHAIRMAN Age | ||
Rodney Sacks | Monster Beverage | 69 | |
Ramakrishnan Chandrasekaran | Cognizant Technology Solutions | 60 | |
Richard Fairbank | Capital One Financial | 72 | |
Lakshmi Narayanan | Cognizant Technology Solutions | 62 | |
Keith Busse | Steel Dynamics | 79 | |
Gary Kelly | Southwest Airlines | 68 | |
John Klein | Cognizant Technology Solutions | 76 | |
Natarajan Narayanan | Cognizant Technology Solutions | 62 | |
Hector Navarro | Grupo Sports World | ||
Robert Switz | Micron Technology | 72 | |
Hilton Schlosberg | Monster Beverage | 70 |
Management Performance
Return On Equity | 0.11 | |||
Return On Asset | 0.0645 |
Novartis AG Leadership Team
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
Ton Buechner, Non-Executive Independent Director | ||
Robert PharmD, Chief Officer | ||
Verena Briner, Non-Executive Independent Member of the Board | ||
Karen Hale, Chief Officer | ||
Chris Ilsley, President CEO | ||
Steven Baert, Chief People & Organization Officer, Member of the Executive Committee | ||
Richard Saynor, Chief Executive Officer of Sandoz, Member of the Executive Committee | ||
Richard Francis, Member of the Executive Committee and Division Head, Sandoz | ||
Daniel Vasella, Honorary Chairman of the Board | ||
Pierre Landolt, Member of the Board of Directors | ||
Elizabeth Doherty, Non-Executive Independent Director | ||
Erwin Vanhaecke, Head Novartis Group Quality | ||
Elizabeth Barrett, CEO, Novartis Oncology | ||
Mark Fishman, Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR) | ||
Charlotte PamerWieser, Corporate Secretary | ||
Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel | ||
Samir Shah, Global Head Investor Relations | ||
David Epstein, Member of the Executive Committee, Division Head, Pharmaceuticals | ||
Srikant Datar, Non-Executive Independent Director | ||
MarieFrance Tschudin, President of Novartis Pharmaceuticals, Member of the Executive Committee | ||
Samir MD, Global Relations | ||
Simon Moroney, Non-Executive Independent Director | ||
Francesco Balestrieri, CEO of Sandoz, Member of the Executive Committee | ||
Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee | ||
Paul Penepent, Head Accounting | ||
Joerg Reinhardt, Independent Non-Executive Chairman of the Board | ||
Paul Hudson, CEO of Novartis Pharmaceuticals, Member of the Executive Committee | ||
Brian McNamara, Member of the Management Board, Division Head, Novartis OTC | ||
Andrews C, Non-Executive Independent Director | ||
Michele Galen, Head Communications | ||
Charles Sawyers, Non-Executive Independent Member of the Board | ||
John Tsai, Head of Global Drug Development and Chief Medical Officer, Member of the Executive Committee | ||
Dimitri Azar, Non-Executive Independent Director | ||
Frans Houten, Non-Executive Independent Director | ||
Nancy Andrews, Non-Executive Independent Director | ||
Susanne Schaffert, President of Novartis Oncology, Member of the Executive Committee | ||
Enrico Vanni, Lead Independent Non-Executive Vice Chairman of the Board | ||
Bertrand Bodson, Chief Digital Officer, Member of the Executive Committee | ||
Robert Weltevreden, Head of Novartis Business Services (NBS), Member of the Executive Committee | ||
Andre Wyss, Member of the Executive Committee, Novartis Business Services and Country President for Switzerland | ||
Bruno Strigini, CEO of Novartis Oncology, Member of the Executive Committee | ||
Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee | ||
Alex Krauer, Honorary Chairman of the Board | ||
Michael Ball, CEO of Alcon, Member of the Executive Committee | ||
Jeffrey George, Member of the Executive Committee and Division Head, Sandoz | ||
Patrice Bula, Non-Executive Independent Director | ||
Peter Kornicker, Chief Compliance Officer | ||
Andreas Planta, Non-Executive Independent Director | ||
Joseph Jimenez, CEO, Member of the Executive Committee | ||
Ulrich Lehner, Vice Chairman of the Board of Directors, Non-Executive Director | ||
William Winters, Non-Executive Independent Member of the Board | ||
Ann Fudge, Non-Executive Independent Director | ||
George Gunn, Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility | ||
Paul Arkel, Head of Corporate Strategy and External Affairs | ||
James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee | ||
Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee | ||
Felix Ehrat, General Counsel and General Counsel of Novartis International Ag | ||
Harry Kirsch, Chief Financial Officer, Member of the Executive Committee | ||
Andrin Oswald, Member of the Executive Committee, Division Head, Vaccines and Diagnostics | ||
Bridgette Heller, Non-Executive Independent Director |
Novartis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.11 | |||
Return On Asset | 0.0645 | |||
Profit Margin | 0.13 % | |||
Operating Margin | 0.25 % | |||
Current Valuation | 4.12 T | |||
Shares Outstanding | 2.12 B | |||
Shares Owned By Institutions | 8.23 % | |||
Price To Earning | 24.95 X | |||
Price To Book | 2.82 X | |||
Price To Sales | 74.58 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novartis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novartis' short interest history, or implied volatility extrapolated from Novartis options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Novartis Stock analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |